Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to Sell at StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Trading Up 1.2 %

Shares of ORMP stock opened at $2.44 on Friday. Oramed Pharmaceuticals has a 12 month low of $2.00 and a 12 month high of $3.67. The stock has a market cap of $98.36 million, a P/E ratio of 22.18 and a beta of 1.70. The company has a 50 day simple moving average of $2.38 and a two-hundred day simple moving average of $2.41.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ORMP. Dimensional Fund Advisors LP increased its stake in shares of Oramed Pharmaceuticals by 52.1% in the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after buying an additional 108,700 shares during the period. XTX Topco Ltd purchased a new stake in Oramed Pharmaceuticals in the 2nd quarter worth $40,000. Murchinson Ltd. raised its holdings in Oramed Pharmaceuticals by 23.2% during the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after acquiring an additional 320,495 shares during the period. Finally, BML Capital Management LLC lifted its position in shares of Oramed Pharmaceuticals by 62.1% in the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after acquiring an additional 837,153 shares in the last quarter. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.